Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan

Songjiang Ma, President of Gyre Therapeutics, sold 4,000 shares of common stock on December 19th and 20th, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Songjiang Ma, the President of Gyre Therapeutics, sold 2,000 shares of common stock on December 19, 2024, at a weighted average price of $10.82 per share.
• The sales occurred within a price range of $10.61 to $11.35.
• Following this transaction, Ma directly owns 0 shares and indirectly owns 2,936,467 shares through his spouse.
• On December 20, 2024, Ma sold another 2,000 shares at a weighted average price of $10.90 per share, with prices ranging from $10.39 to $11.11.
• After the second sale, Ma directly owns 0 shares and indirectly owns 2,934,467 shares through his spouse.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating routine stock sales under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company presidents are common and are often pre-planned to avoid insider trading accusations. The use of a 10b5-1 trading plan is a standard practice for executives to sell shares over time.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholder sentiment, but the pre-planned nature of the sales mitigates this concern.

Key Dates